The impact of pyrvinium pamoate on colon cancer cell viability

International Journal of Colorectal Disease

Volumn 29, Issue 10, 2014, Pages 1189-1198

  Wiegering, Armin ^a,b   Uthe, Friedrich Wilhelm ^b   Hüttenrauch, Melanie ^b   Mühling, Bettina ^a   Linnebacher, Michael ^c   Krummenast, Franziska ^a   Germer, Christoph Thomas ^a   Thalheimer, Andreas ^a,d   Otto, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d Neurologische Klinik Bad Aibling   (Germany)

Author keywords

Colon cancer cell lines; Myc; Pyrvinium pamoate; WNT pathway

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; FLUOROURACIL; PYRVINIUM EMBONATE;

ANIMAL; CELL MOTION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG EFFECTS; HUMAN; IC50; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLONIC NEOPLASMS; FLUOROURACIL; GENES, APC; HETEROGRAFTS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MICE; PYRVINIUM COMPOUNDS; WNT SIGNALING PATHWAY;

EID: 84929132554     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-014-1975-y     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. Cancer J Clin 61:69–90
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B et al (2010) Colorectal cancer. Lancet 375:1030–1047
3. Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1(2):157–162
4. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337
5. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR (2007) Myc deletion rescues Apc deficiency in the small intestine. Nature 446(7136):676–769
6. Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, Baba H, Haga N, Ishida H (2013) Polymorphisms of GSTP1, ERCC2 and TS-3’UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett 6(3):648–654
7. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136(5):823–837
8. Barker N, Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5(12):997–1014
9. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F et al (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264):614–620
10. Tian XH, Hou WJ, Fang Y, Fan J, Tong H, Bai SL, Chen Q, Xu H, Li Y (2013) XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 32(1):100
11. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, Kim K, Melancon B, Ghidu VP, Sulikowski GA, LaFleur B, Salic A, Lee LA, Miller DM 3rd, Lee E (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat Chem Biol 6(11):829–836
12. Venerando A, Girardi C, Ruzzene M, Pinna LA (2013) Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. Biochem J 452(1):131–137
13. Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, Prall F, Linnebacher M (2012) Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One 7(12):e52485
14. Klingelhoeffer C, Kämmerer U, Koospal M, Mühling B, Schneider S, Kapp M, Kübler A, Germer C-T, Otto C (2012) Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress. BMC Complement Altern Med 12:61
15. Langendorf H (1958) Direct complexometric calcium determination in serum with calcein as indicator. Klin Wochenschr 36(17):829–831
16. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M (2002) The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol 160(1):195–204
17. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
18. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RESEARCH0034
19. Thalheimer A, Korb D, Boenicke L, Wiegering A, Muehling B, Schneider M, Koch S, Riedel S, Germer C-T, Braendlein S, Otto C (2013) Non-invasive visualisation of tumour growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging. J Surg Res 195(1):143–151
20. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111(2):241–250
21. Esumi H, Lu J, Kurashima Y, Hanaoka T (2004) Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 95(8):685–690
22. Tomitsuka E, Kita K, Esumi H (2010) The NADH-fumarate reductase system, a novel mitochondrial energy metabolism, is a new target for anticancer therapy in tumor microenvironments. Ann N Y Acad Sci 1201:44–49
23. Tomitsuka E, Kita K, Esumi H (2012) An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system—a unique mitochondrial energy metabolism in tumour microenvironments. J Biochem 152(2):171–183
24. Harada Y, Ishii I, Hatake K, Kasahara T (2012) Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett 319(1):83–88
25. Yu DH, Macdonald J, Liu G, Lee AS, Ly M, Davis T, Ke N, Zhou D, Wong-Staal F, Li QX (2008) Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One 3(12):e3951
26. Deng L, Lei Y, Liu R, Li J, Yuan K, Li Y, Chen Y, Liu Y, Lu Y, Edwards CK 3rd, Huang C, Wei Y (2013) Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis 4:e614
27. Domínguez-Cáceres MA, García-Martínez JM, Calcabrini A, González L, Porque PG, León J, Martín-Pérez J (2004) Prolactin induces Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene 23(44):7378–7390
28. Torti D, Trusolino L (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 3(11):623–636
29. Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C (2012) Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. PLoS One 7(12):e514492